Explore the full record of transactions filed by Albers Jeffrey W., Chairman & CEO. Director active across 1 companies, notably Blueprint Medicines Corp. In total, 14 filings have been published. Total volume traded: €426k. The latest transaction was disclosed on 16 May 2022 — Levée d'options. Regulator: SEC (Form 4). All data is free.
Jeffrey W. Albers is the CEO and President at Blueprint Medicines Corp. He leads the company with a strategic vision focused on innovation in the biopharmaceutical sector. Albers is responsible for implementing growth and product development strategies. His leadership is essential for positioning Blueprint Medicines as a key player in the field of precision medicine.